[en] [en] OBJECTIVES: Our objective was to systematically synthesize and evaluate the existing evidence from meta-syntheses (systematic reviews and meta-analyses) reporting on the safety of celecoxib in adults with chronic musculoskeletal disorders.
METHODS: We conducted a comprehensive literature search in November 2024 across MEDLINE, Cochrane Central, and Scopus databases, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines for umbrella reviews. Only systematic reviews and meta-analyses involving celecoxib safety in osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis were included. We assessed the risk of bias using the AMSTAR-2 tool and graded the certainty of evidence using GRADE.
RESULTS: Of 2294 retrieved records, 16 systematic reviews based on randomized controlled trials met the inclusion criteria (14 of 16 were rated as critically low quality). Celecoxib was consistently associated with a lower risk of gastroduodenal ulcers than were non-selective non-steroidal anti-inflammatory drugs (NSAIDs), and some studies also reported fewer gastrointestinal complaints and serious events with celecoxib than with non-selective NSAIDs. Cardiovascular safety outcomes were generally similar to those with non-selective NSAIDs, although one meta-analysis showed a lower risk of cardiovascular mortality with celecoxib. Compared with placebo or non-selective NSAIDs, celecoxib did not increase the risk of renal dysfunction or elevated creatinine and may be associated with fewer renal adverse events. Evidence on all-cause mortality was limited and inconsistent, but one study suggested a lower risk than with non-selective NSAIDs.
CONCLUSIONS: Celecoxib appears to offer better gastrointestinal safety than non-selective NSAIDs. Although data on cardiovascular, renal, and mortality outcomes suggest possible advantages, the evidence remains limited and of low certainty. Moreover, some real-world evidence raises concerns in specific high-risk populations. Future research should integrate data from both randomized trials and observational studies to better inform long-term safety assessments and guide individualized treatment decisions.
Disciplines :
Rheumatology
Author, co-author :
Beaudart, Charlotte ; Public Health Aging Research & Epidemiology (PHARE) Group, Research Unit in Clinical, Pharmacology and Toxicology (URPC), NAmur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium. charlotte.beaudart@unamur.be
Brabant, Christian ; Université de Liège - ULiège > Département de Psychologie > Méta-recherche et éthique de la méthodologie quantitative
Alokail, Majed; Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Reginster, Jean-Yves; Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review.
This work was supported by Viatris. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. J-YR\u2019s participation in this work was supported by the Distinguished Scientist Fellowship Program (DSFP) of the King Saud University, Riyadh, Kingdom of Saudi Arabia.
GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet 396 10258 1204 1222
A.M. Briggs et al. Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on ageing and health Gerontologist 56 Suppl 2 S243 S255 26994264
N. Veronese et al. Mediterranean diet and osteoarthritis: an update Aging Clin Exp Res 36 1 231 39625615 11614952
X. Lan et al. Physical modalities for the treatment of knee osteoarthritis: a network meta-analysis Aging Clin Exp Res 37 1 121 40192971 11976336
C. Beaudart et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon Drugs 80 18 1947 1959 1:CAS:528:DC%2BB3cXitFKltr3J 33074440 7716887
K. Ma et al. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis Arch Med Sci 15 1 33 54 1:CAS:528:DC%2BC1MXitlKmsL%2FN 30697252
A. Shetty et al. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain Sci Rep 14 1 1621 1:CAS:528:DC%2BB2cXislGnsb8%3D 38238384 10796361
C. Cooper et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging 36 Suppl 1 15 24 31073921 6509083
I.L.P. Beales Time to reappraise the therapeutic place of celecoxib Ther Adv Chronic Dis 9 5 107 110 29796239 5956647
D. Moher et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 7 19622551 2714657 b2535
E. Aromataris et al. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach Int J Evid Based Healthc 13 3 132 140 26360830
A. Morrison et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies Int J Technol Assess Health Care 28 2 138 144 22559755
A.I. Dobrescu et al. Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review J Clin Epidemiol 137 209 217 1:STN:280:DC%2BB3sbovVOmtw%3D%3D 33933579
G. Jamtvedt et al. Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews Phys Ther 88 1 123 136 17986496
D.M. Ashcroft et al. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib Ann Pharmacother 35 7–8 829 834 1:CAS:528:DC%2BD3MXmtVOjsbo%3D 11485128
B.R. Cheng et al. Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: a systematic review and meta-analysis PLoS ONE 16 12 1:CAS:528:DC%2BB38Xpt1Krsw%3D%3D 34932581 8691614 e0261239
S. Garner et al. Celecoxib for rheumatoid arthritis Cochrane Database Syst Rev 4 3831
M. Fidahic et al. Celecoxib for rheumatoid arthritis Cochrane Database Syst Rev 6 6 2095
L. Puljak et al. Celecoxib for osteoarthritis Cochrane Database Syst Rev 5 5 9865
S. Jarupongprapa P. Ussavasodhi W. Katchamart Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis J Gastroenterol 48 7 830 838 1:CAS:528:DC%2BC3sXhtFCrtbzO 23208017
X. Wang et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis Eur J Gastroenterol Hepatol 23 10 876 880 1:CAS:528:DC%2BC3MXhtFGitL%2FM 21900785
R.A. Moore et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports Arthritis Res Ther 7 3 R644 R665 1:CAS:528:DC%2BD2MXkt1Cjsr4%3D 15899051 1174947
J. Zhang E.L. Ding Y. Song Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials JAMA 296 13 1619 1632 1:CAS:528:DC%2BD28XhtVCqu7fM 16968832
C. Zeng et al. Effectiveness and safety of glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee Sci Rep 5 16827 1:CAS:528:DC%2BC2MXhvVOrurfP 26576862 4649492
A. Rostom et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review Clin Gastroenterol Hepatol 5 7 818 828 17556027
M. Fan et al. Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials Exp Ther Med 19 4 3031 3041 1:CAS:528:DC%2BB3cXhvVaksrfI 32256790 7086213
S.R. Mallen M.N. Essex R. Zhang Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs Curr Med Res Opin 27 7 1359 1366 1:CAS:528:DC%2BC3MXnsFOjs70%3D 21561397
R. Wang A. Dasgupta M.M. Ward Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials Ann Rheum Dis 75 6 1152 1160 1:CAS:528:DC%2BC2sXivV2qt7c%3D 26248636
C. Xu et al. Efficacy and safety of celecoxib therapy in osteoarthritis: a meta-analysis of randomized controlled trials Medicine (Baltimore) 95 20 1:CAS:528:DC%2BC28XotF2gtrs%3D 27196460 e3585
J.J. Deeks L.A. Smith M.D. Bradley Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials BMJ 325 7365 619 1:CAS:528:DC%2BD38Xot1GhsL4%3D 12242171 126301
F.E. Silverstein et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 10 1247 1255 1:CAS:528:DC%2BD3cXmvFKmuro%3D 10979111
G. Honvo et al. Safety of anti-osteoarthritis medications: a systematic literature review of post-marketing surveillance studies Drugs 85 4 505 555 1:CAS:528:DC%2BB2MXnvVyisb0%3D 40095377
O. Bruyere et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Semin Arthritis Rheum 49 3 337 350 31126594
R.R. Bannuru et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis Osteoarthritis Cartilage 27 11 1578 1589 1:STN:280:DC%2BB3MzkslSqsw%3D%3D 31278997
G. Herrero-Beaumont et al. Systemic osteoarthritis: the difficulty of categorically naming a continuous condition Aging Clin Exp Res 36 1 45 38376694 10879223
C.J. Hawkey COX-1 and COX-2 inhibitors Best Pract Res Clin Gastroenterol 15 5 801 820 1:CAS:528:DC%2BD38Xhs1KltA%3D%3D 11566042
E.J. Topol Failing the public health – rofecoxib, Merck, and the FDA N Engl J Med 351 17 1707 1709 1:CAS:528:DC%2BD2cXovFSks7g%3D 15470193
P. McGettigan D. Henry Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 13 1633 1644 1:CAS:528:DC%2BD28XhtVGjsrjL 16968831
S.E. Nissen et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis N Engl J Med 375 26 2519 2529 1:CAS:528:DC%2BC2sXhvVSmtQ%3D%3D 27959716
D.H. Solomon et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial Am J Med 130 12 1415 1422 1:CAS:528:DC%2BC2sXhsVWmsbbE 28756267
N.D. Yeomans et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial Aliment Pharmacol Ther 47 11 1453 1463 1:CAS:528:DC%2BC1cXhtVOmt77P 29667211
F. Ruschitzka et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen ambulatory blood pressure measurement) trial Eur Heart J 38 44 3282 3292 1:CAS:528:DC%2BC1MXhslemsrw%3D 29020251 8139400
S. Obeid et al. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial Eur Heart J 8 6 611 621
P. McGettigan D. Henry Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies PLoS Med 8 9 1:CAS:528:DC%2BC3MXhtlCjsrnE 21980265 3181230 e1001098
S.S. Antonioli et al. Rates of postoperative heart failure among type 2 diabetics with use of nonsteroidal anti-inflammatory drugs for total knee arthroplasty J Arthroplasty 40 7S1 S184 S187 40086643
A. Kim et al. Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study Scand J Rheumatol 54 3 204 212 1:STN:280:DC%2BA3c%2FmtFOjug%3D%3D 40028763
